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Introduction
Coronavirus (CoV) is a positive single stranded RNA 
virus which causes a respiratory tract infection in 
human [1]. Earlier in 2002 and 2012, the emergence of 
severe acute respiratory syndrome (SARS) coronavirus 
(SARS-CoV) and Middle East respiratory syndrome 
(MERS) coronavirus (MERS-CoV) have attracted the 
researchers to explore the epidemic potential [1] of these 
viruses. A newly discovered `-coronavirus led to the 
occurrence of a number of pneumonia cases in Wuhan, 
China, in December 2019. Initially (on 12  January 
2020), it was given the name, the 2019-novel coronavirus 
(2019-nCoV) by the World Health Organisation 
(WHO). Later, the disease was officially renamed as 
coronavirus disease 2019 (COVID-19) by WHO. The 
new coronavirus was termed as SARS-CoV-2 by the 
Coronavirus Study Group (CSG) of the International 
Committee, on 11 February 2020 [2]. The SARS-CoV-2 
also develops an upper respiratory tract infection much 
alike its earlier ancestor SARS-CoV, however, the recent 
pandemic due to this novel mutated SARS-CoV-2 virus 
infection created a critical pandemic situation throughout 
the globe [3]. Until now, different researches are being 
performed to understand the infection severity and virus 
transmissibility of novel SARS-CoV-2. Keeping in view 
the above perspective, an attempt is made in order to find 
out the epidemiological pattern of COVID-19 pandemic, 
if any in different geo-climatological regions of the world 
in terms of case incidence and mortality. In addition, 
this study is also an endeavor to review and analyze the 
gradual changes of the genetic makeup of SARS-CoV 
from evolutionary and epidemiological perspectives. 
Coronavirus (CoV) and its characteristics
Coronaviruses are non-segmented, enveloped and 
positive sense single-stranded RNA virus genomes. 
They have a size ranging from 26 to 32 kilobases. The 
virion consists of a nucleocapsid composed of genomic 
RNA and phosphorylated nucleocapsid (N) protein, 
covered by two different types of spike proteins: the 
hemagglutinin-esterase (HE) (found in some CoVs) 
and the spike glycoprotein trimmer (S) (found in all 
CoVs). The S protein in the virus envelop consists of the 
membrane (M) protein and the envelope (E) protein [2]. 
The _,`, a and b coronaviruses are the four genera into 
which the coronavirus subfamily is genotypically and 
serologically divided  [4]. Gastroenteritis in animals 
and respiratory illness in humans are caused by 
_-coronaviruses and `-coronaviruses. The two deadly 
and extremely pathogenic `-coronaviruses and 2002 
SARS-CoV and the 2012 MERS-CoV, cause severe 
respiratory diseases in humans. HCoV-NL63 and HCoV-
229E, the _-coronaviruses and HCoV-OC43 and HKU1, 
SARS-CoV-2 is a new form of `-coronavirus that has been 
recently discovered and is responsible for COVID 19 pandemic. 
The earliest infection can be traced back to Wuhan, China. From 
there it has spread all over the world. Keeping in view the above 
perspective, an attempt is made in order to find out the epidemio-
logical pattern of COVID 19 pandemic, if any, in different geo-
climatological regions of the world in terms of case incidence and 
mortality. This study is also an endeavor to review and analyze 
the gradual changes of the genetic makeup of SARS-CoV from 
evolutionary and epidemiological perspectives. The raw data of 
COVID-19 cases and death incidences were collected from the 
World Health Organization (WHO) website from the time period: 
1st April to 6th April, 2020. The data that are utilized here for gen-
eral and Case fatality rate (CFR) based analysis. Western pacific 
region, European region and Americas have the greatest number 
of infected cases (P < 0.001); whereas deaths have been found 
to be significantly higher in Europe (P < 0.001). Total number of 
confirmed cases and deaths in south-east Asia are comparatively 
lower (P < 0.001). Case fatality rate (CFR) has also found signifi-
cant for European region. SARS-CoV-2 is considered to be a strain 
of SARS-CoV that has a high rate of pathogenicity and trans-
missibility. Result indicated that the European region has been 
affected mostly for both cases and death incidences. The novel 
mutations in SARS-CoV-2 possibly increase the virus infectivity. 
Genetic heterogeneity of this virus within the human population 
might originate as the representatives of naturally selected virus 
quasispecies. In this context, the presence of the asymptomatic 
individuals could be a significant concern for SARS-CoV-2 epi-
demiology. Further studies are required to understand its genetic 
evolution and epidemiological significance.
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the `-coronaviruses, are the four human coronaviruses 
that cause mild upper respiratory syndromes in immuno-
competent hosts, though severe infections can be caused 
by few of them in infants, young children, elderly 
people and immune-compromised individuals [5-7]. The 
majority COVID-19 infection remains asymptomatic or 
mild. The non-SARS like CoVs are responsible for upper 
respiratory tract (20%) infections in adult individuals. 
However, these non-SARS like CoVs are often associated 
with severe acute respiratory illness (SARI) in elderly 
people and immunosuppressed individuals  [8]. All 
human coronaviruses are considered to have an animal 
origin, according to the recent sequence databases. 
Among them, SARS-CoV, MERS-CoV, SADS, HCoV-
NL63 and HCoV-229E are recognized to have an origin 
in bats, while HCoV-OC43 and HKU1 are considered to 
have an origin in rodents [5]. The zoonotic transmission 
of virus from natural hosts to humans may certainly be 
carried out by domestic animals that portray an important 
part as intermediate hosts. These domestic animals can 
also be infected by spillover of the diseases caused by 
bat-borne or closely related coronaviruses  [5,  9,  10]. 
The SARS-CoV-2 is also considered to have a zoonotic 
origin and has a close genetic resemblance to the bat 
coronaviruses that suggests it has emerged as a bat-borne 
virus  [11, 12]. Additionally, introduction to humans is 
also thought to be brought about by pangolin that serves 
as an intermediate animal reservoir  [13]. Several dogs 
and cats (domestic cats and a tiger) have tested positive 
to COVID-19 virus following close contact with infected 
humans [14].
SARS-CoV-2 and COVID-19
On 11 February 2020, the International Committee 
of Taxonomy of Viruses (ICTV) announced that, the 
differences between 2019-nCoV and the virus strain 
from the 2003 SARS outbreak were not enough to 
declare them to be separate viral species; as per the 
rules that calculate hierarchical relationships among 
different coronaviruses on the basis of five conserved 
nucleic acid sequences. Hence, 2019-nCoV was 
identified as a Severe Acute Respiratory Syndrome-
related Coronavirus. Taxonomically, SARS-CoV-2 
was thus declared to be a strain of SARS-CoV-2 [15] 
which is responsible for COVID-19. The genome of 
the coronaviruses is seen to contain variable numbers 
(6-11) of open reading frames (ORFs)  [11]. 16 non-
structural proteins (NSP) are encoded by two-thirds 
of viral RNA located in the first ORF. The spike (S) 
glycoprotein, small envelope (E) protein, matrix 
(M) protein, nucleocapsid (N) protein and many 
accessory proteins are encoded by the viral genome 
that play an important role in the host innate immune 
response [2, 5]. Certain degree of similarity has been 
found in the S-glycoprotein gene and receptor-binding 
domain (RBD) of SARS-CoV-2 and SARS-CoV. This 
explains the capability of direct human transmission 
of SARS-CoV-2  [5]. High infectious capability of 
SARS-CoV-2 is attributed by novel mutations in their 
non-structural proteins. Two predominant evolvement 
types of SARS-CoV-2 include the L type (~70%) and 
the S type (~30%) strains. The L type strains have 
derived from the S type and are more aggressive and 
contagious, evolutionarily [16].
Aspects of SARS-CoV-2 infection 
SARS-CoV uses ACE2 as its cellular receptor, which is 
found in the lower respiratory tracts of humans. It has 
also been confirmed that SARS-CoV-2 also uses the same 
cellular receptor, ACE2, to gain entry into the host cells. 
The S-glycoprotein on the surface of the coronavirus can 
attach to ACE2 on the surface of the human cells [2, 12]. 
Among all the known `-coronaviruses, SARS-CoV-2 
is distinct because of the presence of two of the most 
important genomic factors that increase the pathogenicity 
and transmissibility of the virus (Fig. 1): 
1. polybasic furin cleavage site and O-linked glycans: 
A polybasic cleavage site is present at the junction of 
S1 and S2, the two spike subunits, in SARS-CoV-2. 
Thus, furin and other proteases can carry out effec-
tive cleavage, which in turn plays a major role in es-
tablishing viral infectivity and host range; 
2. mutations in the receptor binding domain (RBD) of 
SARS-CoV-2. The most flexible part of the corona-
virus genome is the RBD in the spike protein. The 
RBD of SARS-CoV-2 binds with high affinity to the 
ACE2 of humans, ferrets, cats and other species with 
high receptor homology [17, 18].
Materials and methods
The raw data of COVID-19 cases and death incidences 
were collected from the World Health Organization 
(WHO) website [19]. Data that are utilized here for 
analysis were taken from the time period: 1st April to 
6th April, 2020. These were initially arranged in groups 
according to different geo-climatic regions. Then the 
case fatality rate (CFR) is calculated by the following 
way:
Number of death incidence/  
total number of case incidence * 100%
Statistical differences between standard error of the 
means (SEM) of the studied groups were assessed using 
one-way analysis of variance (ANOVA) followed by 
suitable post-hoc test (i.e. Bonferroni test). Level of 
statistical significance is expressed through the P-value: 
P < 0.001, P < 0.01 and P < 0.05. 
Results
It can be seen from Figure 2, that Western Pacific region, 
European region and Americas have the greatest number 
of infected cases (P < 0.001); whereas deaths have been 
found to be significantly higher in Europe (P < 0.001). 
On the other hand, the total number of confirmed cases 
and deaths in South-Eastern Asia are comparatively 
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lower than that of Europe and America (P < 0.001) [19] 
(Fig. 2). Case fatality rate (CFR) was also found to be 
significant for European region. Hence, it has been 
clearly seen that the European region have been affected 
mostly (P < 0.001) with respect to the number of cases 
and deaths. This disease severity might be linked to the 
genetic uniqueness of the mutated SARS-CoV-2. 
Discussion
Epidemiological study from the result section indicates 
COVID-19 cases and deaths are significant in both 
European and American region. This global pandemic 
situation due to COVID-19 is caused by SARS-
CoV-2, which is a new form of `-coronavirus that has 
Fig. 1. Major structural characters of SARS-CoV-2 [17].
Fig. 2. Effect of COVID-19 on human population. A) total number of confirmed COVID 19 cases; B) total number of deaths in different 
regions within the globe from 1st to 6th April, 2020; C) Case Fatality Rate (%) of COVID-19 on 6th April, 2020. Bars indicate percentage of 
statistical errors of the CFR data [19]. 
CHANGING EPIDEMIOLOGY OF SARS-COV IN THE CONTEXT OF COVID-19 PANDEMIC
E133
been recently discovered. SARS-CoV-2 is considered 
to be a strain of SARS-CoV that has a high rate of 
pathogenicity and transmissibility. European countries 
have been affected severely (cases and deaths) by the 
virus than the other regions (Tabs.  I,  II). The highest 
death rate has been found significant between 50-80 
years of age [19] (Tab. II). The mutation in the receptor 
binding domain and the polybasic furin cleavage site on 
the spike protein might be the major contributor of the 
significant infectivity and transmissibility to the virus. 
However, research indicated that different transition 
type of point mutation causes the virus heterogeneity 
in different geographical regions [20]. These ultimately 
affect the virus infectivity. Interestingly, the individuals 
over 60  years are developing severe pneumonia  [21]. 
This might be due to the genetic structure of the virus 
which affects the low immunity of elderly individuals. 
However, different immune-pathological factors can 
also play a role in this. The exact process of affecting the 
immune system by SARS-CoV-2 is still unclear, however 
it can be said that virus like SARS-CoV after entering 
into human body is recognized by different receptors 
(like Toll Like Receptor [TLR], Pattern Recognition 
Receptor [PRR]) and induces response like expression 
of inflammatory factors, synthesis of type I interferon. In 
this context, it is relevant to mention that SARS-CoV has 
the ability to bypass this strong immunological barrier 
through the activity of its N protein. This supports the 
high infectivity of the virus [21]. 
The significant cases and deaths found throughout the 
different geo-climatic regions (i.e. Western Pacific, 
Europe, America, Eastern Mediterranean, South East 
Asia) due to SARS-CoV-2 is potentially caused by 
mutational changes in the virus genome. The novel 
mutations in SARS-CoV-2 possibly increase the virus 
infectivity through the introduction of unique mutations 
in their RNA genome. It has been found that there are 
ninetythree mutations are present in the entire genome 
of SARS-CoV-2. Among them, 42 missense mutations 
are found within the non-structural and structural protein 
of the virus. In addition, 29 and 8 missense mutations 
were located in the ORF1ab polyprotein region and 
spike protein [22]. However, the mutation in the receptor 
binding domain and the polybasic furin cleavage site on 
the spike protein might be the major contributor of the 
significant infectivity and transmissibility to the virus.
The significant cases of COVID-19 throughout different 
climatic regions possibly indicate the SARS-CoV-2 RNA 
genome fitness. In this context, virus quasispecies might 
play a significant role in virus heterogeneity. It has been 
stated that, RNA virus quasispecies could successfully 
bypass host immune system and its response; which 
might further increase the genetic diversity of the 
virus [23, 24]. This viral RNAs of the quasispecies from 
naturally “fit” RNA virus population will increase the 
potential risk of infection and disease severity  [23], 
which could ultimately affect the known face and nature 
of SARS-CoV epidemiology. 
The high CFR and case incidences in European and 
American regions indicate the disease severity of 
COVID-19. This disease severity could also be attributed 
to antibody-dependent enhancement phenomenon 
(ADE). ADE is caused by non-neutralizing antiviral 
proteins that facilitate virus entry into the host cells, 
causing enhanced infectivity in the cells  [25]. In case 
of ADE, a high-affinity memory B cell, specific for a 
particular virus (For eg, Virus  A), is preferentially 
activated by a new serotype of the virus (For eg, 
Virus A1), to produce antibodies that bind ineffectively 
to this new serotype. The presence of these ineffective 
antibodies inhibits activation of naive B cells that could 
produce more effective antibodies against the new 
serotype. This causes a reduced immune response against 
the new serotype and increases the potential for serious 
infection. This condition has already been reported 
in case of other RNA viruses like Dengue virus. Four 
antigenically different serotypes of dengue virus  (1-4) 
exist. Infection with one serotype leads to the production 
of neutralizing homotypic IgG antibodies that provide 
lifelong immunity against that particular serotype. The 
phenomenon of ADE is seen when a different serotype 
of the dengue virus infects a person within months or 
Tab. I. COVID-19 cases comparison between different geographical regions (from 1st to 6th April 2020) [19].
Geographical regions COVID-19 cases Affected age groups
Western Pacific and Europe Significant in Europe (P < 0.001)
50-80 years
Western Pacific and Southeast Asia Significant in Western Pacific (P < 0.01)
Western Pacific and Regions of Americas Significant in region of Americas (P < 0.001)
Western Pacific and Africa Significant in Western Pacific (P < 0.001)
Europe and South East Asia, Region of Americas, 
Eastern Mediterranean, Africa Significant in Europe (P < 0.001)
Region of Americas and Southeast Asia, Africa, 
Eastern Mediterranean Significant in region of Americas (P < 0.001)
Tab. II. Comparison of death incidences due to COVID-19 between different geographical regions (from 1st to 6th April 2020) [19].
Geographical regions Deaths due to COVID-19 Mostly affected age group 
Europe and Western Pacific, South East Asia, 
Region of Americas, Eastern Mediterranean, Africa Significant in Europe (P < 0.001)
Over 60 yearsSouth East Asia and region of Americas Significant in region of Americas (P < 0.05)
Region of Americas and Africa Significant in region of Americas (P < 0.05)
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years of the first infection by a serotype different from 
the currently infecting one. In such cases, the clinical 
manifestations of the secondary infection are much more 
severe than the primary infection [26]. Study indicated 
that coronavirus like HCoV NL63 has been circulating 
in human population for centuries and this virus and 
SARS-CoV-2 are possible serotypes which are using 
similar mechanism for the cell entry  [4,  27], thus this 
ADE phenomenon might play an important role in 
increasing the SARS-CoV-2 infectivity and disease 
severity leading to COVID-19 pandemic. 
In the context of disease severity and epidemiological 
complexity, the asymptomatic cases have the notable 
importance. Recent research indicated that 1-2% of the 
cases in the Chinese population during COVID-19 were 
asymptomatic [28]. It has been documented that, as of 
February 11, 2020, there were 72, 314 cases probably 
involves the asymptomatic individuals [29]. These 
asymptomatic cases are associated with mild COVID-19 
symptoms. The development of a significant viral load 
within the asymptomatic human individual could further 
facilitate the virus transmission and thereby complicate 
the disease situation. Thus, in depth study is required to 
understand the behavior and role of asymptomatic cases 
in COVID-19 pandemic.
On the other hand, the higher COVID-19 death 
incidences were often associated with the complex 
response of human immune system. It has been found 
that patients with COVID-19 are often associated 
with cytokine storm syndrome. This is a systemic 
inflammatory response of the innate immune system 
in response to a bacterial/viral infection which can 
lead to multi organ failure [21, 30]. Research indicated 
that one of the reasons of the significant mortality in 
COVID-19 is hyper-inflammation and lung injury which 
might be caused from the “cytokine storm” effect [30]. 
This observation can be correlated with the fact that, 
COVID-19 causes notable mortality to elder groups 
throughout the world as elder people are much more 
prone to respiratory inflammatory problems which could 
ultimately lead to lung injury. The high case incidence 
of COVID-19 in western part of world (i.e. Europe and 
America) compared to the South East Asia and Western 
Pacific indicates that the temperature might play a 
significant role in CoV infection. Research demonstrated 
that SARS-CoV2 is notably stable in low temperature 
like 4ºC  [31]. This observation can be correlated with 
the prevalence of COVID-19 cases and deaths in the 
temperate regions of Europe. However, the tropical 
regions like south-east Asia have also shown notable 
COVID-19 cases, which left the further possibility of 
research in this direction. 
Conclusions
COVID-19 has become a pandemic, which leads to 
the death of large individuals of the entire population 
of Earth. SARS-CoV-2 is a novel virus which harbors 
significant genetic mutations that are completely new 
to the innate immune system of the human population. 
Thus, this virus was capable of affecting a large section 
of the human populations. Western pacific region, 
European region and Americas have the greatest 
number of infected cases. European region has been 
affected mostly for both cases and death incidences. 
SARS-CoV-2 is the highly contagious representative 
of coronavirus that contains mutated genomic content. 
This mutation might play a key role in the directional 
selection of this group of viruses in their evolution. 
The recent researches of virus heterogeneity across the 
continents probably indicate the probable existence 
and role of viral quasispecies, shaping and facilitating 
the natural selection of the coronavirus and thereby 
facilitate further emergence as a novel mutated virus 
which can adapt to the different eco-climatic regions. 
This can be supported by recent research where different 
subtypes of the virus have been found responsible for the 
infection. The presence of the asymptomatic individuals 
could further be a significant concern for SARS-CoV-2 
epidemiology. As the asymptomatic person will act as 
a carrier for the virus, determination and isolation of 
the symptomatic patients will not be helpful to manage 
this present epidemic. Thus, sustained testing for the 
virus infection is recommended largely by the scientific 
community. On the other hand, asymptomatic carriers 
could play a notable role as a “mixing pot” for the virus 
subtypes and thus might develop different viral strain 
within the human body. RNA virus infections involve 
an “amplification host” which amplifies the virus. These 
asymptomatic SARS-CoV carriers could possibly act as 
both, “amplifying host” and “mixing pot” and may create 
a more complex epidemiological situation. However, 
more studies are required in this direction to prove this 
hypothesis. Undoubtedly, SARS-CoV-2 is a virus with 
altered genetic makeup and this introduces a selection 
pressure to the human immune system. Hence, over a 
period of time, herd immunity can become an important 
phenomenon to reduce the severity of the virus. 
However, this will be a time-dependent phenomenon. 
On the other hand, the continuous genetic mapping is 
required which will elaborate the understanding of the 
virus “mutation spectrum” that will further facilitate 
the development of a vaccine. Further studies with deep 
genomic sequencing and identification of mutations are 
required to understand the evolving faces of SARS-CoV 
and its epidemiological significance. 
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